Literature DB >> 28825395

Designing and developing suppository formulations for anti-HIV drug delivery.

Anthony S Ham1, Robert W Buckheit1.   

Abstract

Despite a long history of use for rectal and vaginal drug delivery, the current worldwide market for suppositories is limited primarily due to a lack of user acceptability. Therefore, virtually no rational pharmaceutical development of antiviral suppositories has been performed. However, suppositories offer several advantages over other antiviral dosage forms. Current suppository designs have integrated active pharmaceutical ingredients into existing formulation designs without optimization. As such, emerging suppository development has been focused on improving upon the existing classical design to enhance drug delivery and is poised to open suppository drug delivery to a broader range of drugs, including antiretroviral products. Thus, with continuing research into rational suppository design and development, there is significant potential for antiretroviral suppository drug delivery.

Keywords:  antiviral; drug delivery; formulation strategies; pessary; suppository

Mesh:

Substances:

Year:  2017        PMID: 28825395      PMCID: PMC6123880          DOI: 10.4155/tde-2017-0056

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  67 in total

1.  Assessing microbicide acceptability: a comprehensive and integrated approach.

Authors:  Kathleen M Morrow; Monica S Ruiz
Journal:  AIDS Behav       Date:  2007-06-26

2.  Reformulated tenofovir gel for use as a dual compartment microbicide.

Authors:  Charlene S Dezzutti; Lisa C Rohan; Lin Wang; Kevin Uranker; Cory Shetler; Marilyn Cost; J D Lynam; David Friend
Journal:  J Antimicrob Chemother       Date:  2012-05-11       Impact factor: 5.790

3.  Rectal drug administration in adults: how, when, why.

Authors:  Michael Lowry
Journal:  Nurs Times       Date:  2016 Feb 24-Mar 1

4.  Psychometric Properties and Validity of a Multi-dimensional Risk Perception Scale Developed in the Context of a Microbicide Acceptability Study.

Authors:  Sara E Vargas; Joseph L Fava; Lawrence Severy; Rochelle K Rosen; Liz Salomon; Lawrence Shulman; Kate Morrow Guthrie
Journal:  Arch Sex Behav       Date:  2015-11-30

5.  Development of a combination microbicide gel formulation containing IQP-0528 and tenofovir for the prevention of HIV infection.

Authors:  Anthony S Ham; Shweta R Ugaonkar; Lianjun Shi; Karen Watson Buckheit; Howard Lakougna; Umadevi Nagaraja; Garry Gwozdz; Laurie Goldman; Patrick F Kiser; Robert W Buckheit
Journal:  J Pharm Sci       Date:  2012-01-06       Impact factor: 3.534

Review 6.  Will dapivirine redeem the promises of anti-HIV microbicides? Overview of product design and clinical testing.

Authors:  José das Neves; João Pedro Martins; Bruno Sarmento
Journal:  Adv Drug Deliv Rev       Date:  2015-12-28       Impact factor: 15.470

7.  Women's anal sex practices: implications for formulation and promotion of a rectal microbicide.

Authors:  T M Exner; J Correale; A Carballo-Diéguez; L Salomon; K M Morrow; C Dolezal; K Mayer
Journal:  AIDS Educ Prev       Date:  2008-04

8.  Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial.

Authors:  Heather A Pines; Pamina M Gorbach; Robert E Weiss; Kristen Hess; Ryan Murphy; Terry Saunders; Joelle Brown; Peter A Anton; Ross D Cranston
Journal:  AIDS Behav       Date:  2013-03

9.  The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.

Authors:  Kathleen Morrow; Rochelle Rosen; Linda Richter; Anne Emans; Anna Forbes; Jennifer Day; Neetha Morar; Lisa Maslankowski; Albert T Profy; Cliff Kelly; Salim S Abdool Karim; Kenneth H Mayer
Journal:  J Womens Health (Larchmt)       Date:  2003-09       Impact factor: 2.681

10.  Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy.

Authors:  Justin T Clark; Meredith R Clark; Namdev B Shelke; Todd J Johnson; Eric M Smith; Andrew K Andreasen; Joel S Nebeker; Judit Fabian; David R Friend; Patrick F Kiser
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more
  6 in total

1.  Designing Dual Compartment HIV Prevention Products: Women's Sensory Perceptions and Experiences of Suppositories for Rectal and Vaginal Use.

Authors:  Kate M Guthrie; Rochelle K Rosen; Melissa Guillen; Jaime J Ramirez; Sara E Vargas; Joseph L Fava; Anthony S Ham; David F Katz; Susan Cu-Uvin; Sheila Tumilty; Kelley A Smith; Karen W Buckheit; Robert W Buckheit
Journal:  AIDS Res Hum Retroviruses       Date:  2021-10-18       Impact factor: 1.723

2.  Acceptability of a Dapivirine/Placebo Gel Administered Rectally to HIV-1 Seronegative Adults (MTN-026).

Authors:  José A Bauermeister; Ryan C Tingler; Clara Dominguez; Eileen F Dunne; Craig Hoesley; Ken Ho; Sherri Johnson; Jonathan Lucas; Nicole Macagna; Elizabeth Brown; Holly Gundacker; Melissa Peda; Cindy E Jacobson; Lindsay Kramzer; Devika Singh; Charlene S Dezzutti; Ratiya Pamela Kunjara Na Ayudhya; Mark A Marzinke; Jeanna Piper; Bríd Devlin; Jeremy Nuttall; Ian McGowan; Craig W Hendrix; Ross D Cranston
Journal:  AIDS Behav       Date:  2021-10-17

Review 3.  Physiological and Pharmaceutical Considerations for Rectal Drug Formulations.

Authors:  Susan Hua
Journal:  Front Pharmacol       Date:  2019-10-16       Impact factor: 5.810

4.  Nanoformulated Eudragit lopinavir and preliminary release of its loaded suppositories.

Authors:  Lebogang Katata-Seru; Babatunde Moses Ojo; Omotunde Okubanjo; Rebeccah Soremekun; Oluwole Samuel Aremu
Journal:  Heliyon       Date:  2020-05-07

Review 5.  Innovations in Pediatric Drug Formulations and Administration Technologies for Low Resource Settings.

Authors:  Stephen E Gerrard; Jennifer Walsh; Niya Bowers; Smita Salunke; Susan Hershenson
Journal:  Pharmaceutics       Date:  2019-10-08       Impact factor: 6.321

Review 6.  Transmucosal drug administration as an alternative route in palliative and end-of-life care during the COVID-19 pandemic.

Authors:  Jenny K W Lam; Chucky C K Cheung; Michael Y T Chow; Emily Harrop; Susie Lapwood; Stephen I G Barclay; Ian C K Wong
Journal:  Adv Drug Deliv Rev       Date:  2020-11-01       Impact factor: 15.470

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.